Beam Therapeutics Inc. (BEAM)
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Beam Therapeutics Inc. (“Beam” or the “Company”) (NASDAQ: BEAM). Investors who purchased Beam shares are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether Beam violated federal securities laws.
On August 1, 2022, Beam issued a press release “announc[ing] that on Friday, July 29, 2022, the company was informed via e-mail communication from the U.S. Food and Drug Administration (FDA) that the BEAM-201 Investigational New Drug (IND) application for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL)/T cell lymphoblastic lymphoma (T-LL) has been placed on clinical hold.” Beam advised investors that “[t]he FDA indicated they will provide an official clinical hold letter to Beam within 30 days.” On this news, Beam’s stock price fell sharply during intraday trading on August 1, 2022.
If you are aware of any facts relating to this investigation or purchased Beam shares, you can assist this investigation. You can also contact Peretz Bronstein or law clerk and client relations manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC represents investors in securities fraud class actions and shareholder derivative suits. The firm has recovered hundreds of millions of dollars for investors nationwide. Attorney advertising. Prior results do not guarantee similar outcomes.